辛伐他汀联合依折麦布对2型糖尿病合并动脉粥样硬化大鼠糖脂及VEGF、IL-1β、CRP水平的影响

Study on the Effect of Simvastatin Combined with Ezetimibe on Glycolipid and Level of VEGF, IL-1β, CRP of Type 2 Diabetes Mellitus with Atherosclerosis Rats

关键词:  辛伐他汀  依折麦布  2型糖尿病  动脉粥样硬化  血管内皮生长因子

Key words:  simvastatin  ezetimibe  type 2 diabetes  atherosclerosis  VEGF

摘要:

目的 探讨辛伐他汀联合依折麦布对2型糖尿病合并动脉粥样硬化大鼠糖脂及血管内皮生长因子（vascular endothelial growth factor，VEGF）、白介素-1β（interleukin-1β，IL-1β）、C反应蛋白（C reactive protein，CRP）水平的影响。方法 选取42只SD大鼠，♂，选取8只给予普通饲料作对照组，另34只复制2型糖尿病合并动脉粥样硬化模型，确定造模成功（处死2只）后，随机分为4组：模型组8只给予高脂饲料，辛伐他汀组8只给予高脂饮食+辛伐他汀，依折麦布组8只给予高脂饮食+依折麦布，联合组8只给予高脂饮食+辛伐他汀+依折麦布。于分组完毕后继续喂养12周测定体质量、空腹血糖（fasting blood glucose，FPG）、空腹胰岛素（fasting insulin，FINS）、胰岛素抵抗（insulin resistance，HOMA-IR），血脂及VEGF、IL-1β、CRP水平。结果 5组大鼠在治疗12周时体质量、FPG、FINS、HOMA-IR，血脂及VEGF、IL-1β、CRP水平均存在变化。在体质量和FPG上，模型组、辛伐他汀组、依折麦布组、联合组、对照组依次降低；在FINS上，对照组、联合组、依折麦布组和辛伐他汀组、模型组依次降低；在HOMA-IR上，联合组、依折麦布组、辛伐他汀组、模型组高于对照组；在甘油三酯（triglyceride，TG）、总胆固醇（total cholesterol，TC）、低密度脂蛋白胆固醇（low density lipoprotein cholesterol，LDL-C）上，模型组、辛伐他汀组和依折麦布组、联合组、对照组依次降低；在HDL-C上，对照组、联合组、依哲麦布组和辛伐他汀组、模型组依次降低；在VEGF、IL-1β及CRP水平上，模型组、辛伐他汀组和依折麦布组、联合组、对照组依次降低。结论 辛伐他汀联合依折麦布可以调节血脂紊乱，下调VEGF和致炎因子IL-1β、CRP水平。

Abstract:

OBJECTIVE To investigate the effect of simvastatin and ezetimibe in the treatment of type 2 diabetes mellitus with atherosclerosis in rats in serum vascular endothelial growth factor(VEGF), interleukin-1β(IL-1β) and C reactive protein(CRP). METHODS The 42 male SD rats were selected, and 8 rats were given normal diet as control group, other 34 rats which were copied type 2 diabetes mellitus with atherosclerosis model, determined the success of the model, were randomly divided into four groups. Eight rats were given high fat die as model group, 8 rats were given high fat diet plus simvastatin as simvastatin group, 8 rats were given high fat diet plus ezetimibe as ezetimibe group, and 8 rats were given high fat diet+simvastatin plus ezetimibe as the combined group. Body mass, fasting blood glucose(FPG), fasting insu(FINS), insulin resistance(HOMA-IR), blood lipid and levels of VEGF, IL-1β, CRP were compared at 12 weeks. RESULTS Body mass, FPG, FINS, HOMA-IR, blood lipid and levels of VEGF, IL-1β, CRP changed after 12 weeks treatment. The body mass and FPG in model group, simvastatin group, ezetimibe group, combination group, control group were gradually reduced; the FINS in control group, combination group, simvastatin group, ezetimibe group, model group were gradually reduced; the HOMA-IR in combined group, ezetimibe group, simvastatin group, model group, control group weer gradually reduced; the TC, TG and LDL-C in model group, simvastatin group, ezetimibe group, combination group, control group were gradually reduced; the HDL-C in control group, combined group, simvastatin group, ezetimibe group, model group were gradually reduced; the VEGF, IL-1β and CRP level in model group, simvastatin group, ezetimibe group, combination group, control group were gradually reduced. CONCLUSION Simvastatin combined with ezetimibe can regulate the blood lipid disorder and down regulation of VEGF and IL-1β and CRP levels.